Gene Logic Inc - Current report filing (8-K)
December 20 2007 - 5:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported):
December
20, 2007 (December 14, 2007)
Ore
Pharmaceuticals Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
|
0-23317
|
|
06-1411336
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
|
50
West Watkins Mill Road, Gaithersburg, Maryland
|
20878
|
|
(Address
of principal executive office)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (301) 987-1700
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligations of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
[ ]
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.135-4(c))
|
Item
3.01.
Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing
On
December 14, 2007, the NASDAQ Stock Market (“NASDAQ”) notified Ore
Pharmaceuticals Inc. (the “Company”) that for the previous 30 consecutive
business days, the bid price of the Company’s publicly held shares had closed
below the minimum $1.00 per share requirement for continued listing on the
NASDAQ Global Market pursuant to Marketplace Rule 4450(a)(5). In
accordance with Marketplace Rule 4450(e)(2), the Company is provided with
one-hundred eighty (180) calendar days, or until June 11, 2008, to regain
compliance with the minimum bid price requirement. If, at any time
prior to June 11, 2008, the minimum bid price of the Company’s publicly held
shares closes at $1.00 per share or more for a minimum of 10 consecutive
business days, the NASDAQ staff will provide written notification that the
Company has achieved compliance with the minimum bid price
requirement. If compliance with Rule 4450(a)(5) cannot be
demonstrated by June 11, 2008, then the NASDAQ staff will provide written
notification to the Company that its securities will be delisted. At
that time, the Company will be permitted to appeal NASDAQ’s determination to a
Listings Qualifications Panel.
The
Company will use its best efforts to regain compliance and fully expects that
it
will regain compliance prior to June 11, 2008.
A
copy of
the Company's press release announcing the notification from NASDAQ is attached
to this Current Report as Exhibit 99.1.
Item
9.01.
Financial Statements
and Exhibits
(d)
Exhibits.
|
Exhibit
Number
|
|
Description
|
|
99.1
|
|
Press
Release dated December 20, 2007
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
ORE
PHARMACEUTICALS INC.
|
|
|
|
|
|
|
|
|
|
/s/
Philip L. Rohrer Jr.
|
|
|
|
|
Philip
L. Rohrer Jr.
Chief
Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
EXHIBIT
INDEX
|
Exhibit
Number
|
|
Description
|
|
99.1
|
|
Press
Release dated December 20, 2007
|
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
From Dec 2023 to Dec 2024
